NASDAQ$AHCO

AdaptHealth Corp. · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Announced financial results for the second quarter ended June 30, 2021.

AdaptHealth Corp. announced strong financial results for the second quarter, driven by the full quarter impact of AeroCare and realization of integration synergies. The company is experiencing organic growth and making strategic acquisitions. They are also increasing financial guidance for fiscal year 2021.

  • Financial results were driven by a full quarter of AeroCare and realization of integration synergies.
  • The business continues to grow organically as well as through strategic acquisitions in key markets.
  • The company acquired several businesses including Spiro Health Services and Healthy Living Medical Supplies.
  • The e-prescribe technology in diabetes has improved patient and provider satisfaction through reduced cycle time.

Headline financials

Total Revenue

$617M

Previous: $232M+165.8%
EPS (adj)

$0.17

Previous: $0.08+112.5%
Capital Expenditures

-$79.4M

Previous: -$10.9M-627.4%
Free Cash Flow

-$289K

Previous: -$6.88M+95.8%
Net Income

$79.1M

Previous: $4.03M+1861.5%
Operating Income

$65.4M

Previous: $16.5M+297.1%
Gross Profit

$126M

Previous: $34.6M+265.0%
Cash & Equivalents

$178M

Previous: $111M+61.1%
Total Assets

$4.69B

Previous: $739M+534.1%
Stock-Based Comp

$7.45M

Previous: $3.24M+129.6%

Revenue & EPS history

AdaptHealth · Revenue · Quarterly

$617M

Q2 2021+165.8%vs Q2 2020
Beat estimate in 4 of 10 quarters(40%)
ActualEstimate

Forward guidance

Based on current business and market trends, the Company is increasing its previously issued financial guidance for fiscal year 2021.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+0.6%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+1.6%

Avg return

30 days after

52%

16 / 31 earnings

Positive

+34.6%

Q4 2023

Best reaction

-27.9%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-10.0%-13.4%-25.6%
Q4 2025-14.2%-11.1%+10.9%
Q3 2025+17.2%+4.5%+3.2%
Q1 2025+1.7%-1.4%+3.7%
Q4 2024+24.4%+33.1%+24.4%
Q3 2024+0.3%-0.6%-4.2%
Q2 2024-17.2%-14.1%+4.6%
Q1 2024-8.6%-8.8%+4.9%
Q4 2023+34.6%+37.9%+50.9%
Q3 2023-23.1%-18.6%-5.6%
Q2 2023+11.1%+4.4%-19.8%
Q1 2023-8.4%-12.2%-13.8%
Q4 2022-27.9%-27.9%-40.6%
Q3 2022-1.6%+8.4%+4.5%
Q2 2022-8.9%-8.2%-25.7%
Q1 2022+23.7%+42.2%+53.6%
Q4 2021+4.1%+2.3%+2.8%
Q3 2021-5.4%-7.2%-24.1%
Q2 2021+16.4%+13.4%+12.3%
Q1 2021-8.5%-14.9%-10.4%
Q4 2020+2.1%+12.4%+21.7%
Q3 2020+2.6%+0.6%+19.5%
Q2 2020+13.9%+18.0%+7.0%
Q1 2020+1.6%+5.8%+5.5%
Q4 2019+1.8%+1.4%-7.7%
Q3 2019-4.1%-4.9%-3.3%
Q2 2019+0.0%+0.0%-0.6%
Q1 2019+0.0%+0.0%+0.3%
Q4 2018+0.6%+0.7%+1.3%
Q3 2018+0.3%+0.1%+0.4%
Q2 2018+0.0%+0.3%+0.1%
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro